| | | 20,000+ Fresh Resumes Monthly | |
|
|
| |
Click here or scroll down to respond to this candidateCandidate's Name
Street Address Highwood Dr.Baltimore, MD Street Address
PHONE NUMBER AVAILABLEEMAIL AVAILABLEEducation:Bachelor of Science, University of Massachusetts at Dartmouth, Dartmouth, MA 1989-1994.Master of Science (Bioinformatics emphasis), Johns Hopkins University, Baltimore, MD, 1999-2002Employment History:Research Specialist, Wilmer Eye Institute, The Johns Hopkins University: October 2022 to September 2022. Assisted Researchers with fluorescence microscopy and image analysis in the lab, kept a library of 10X-tile images, and developed an AI macro to do 3D image mapping of stem cells added to retinal tissues of animals.Research Associate II, Leidos, National Clinical Trial Validation Laboratory, National Cancer Institute: September 2006 to October 2022.. Developed and published 16 protocols used to measure DNA Damage Repair Markers in cancerous nuclei using histological samples prepared for fluorescence and confocal microscopy. I validated diagnostic protocols using laser scanning microscopy and image analysis. I also created 3 macros using imaging software to quantify nuclei and foci from digital images (.tif and .lsm files).SRA-4 Lab Supervisor, Surgery Research Lab, The University of California at San Diego, La Jolla, CA: January 2006 to September 2006. Moved and oversee the equipment and personnel for the lab to further the progress of the research. Main responsibilities include writing protocols needed by the university and the lab, evaluating and purchasing equipment as needed. My project is to design and use an RNAi system to degrade Heat-shock proteins while in the presence of Geldanamyacin.Research Assistant/Lab Manager, GYN/Oncology Pathology Lab, the Johns Hopkins University, Baltimore, MD: October 1998 January 2006. Manage the lab supplies and personnel to further the progress of the research. Manage the collection and banking of over 20,000 tissues received from patients, and responsible for making many of the experiments for the labs biomedical research using cell culture, molecular biology and animal science for the publications of the lab (See attached list).Pharmacology Technician, ProScript, Cambridge, MA: September 1997 September 1998. As part of a team that pushed the research for a novel chemotherapeutic drug into Phase 1 trials within 2 years of discovery. Main duties were to inject cancer cells into mice and rats, treat them with a novel drug, dissect and process specimens, run Bradford and Hemoglobin assays, and catalog the specimens, as well as maintaining the animal colony. Other duties included managing data, creating graphs for publication, and presenting data at meetings.Manufacturing Technician, Creative Biomolecules, Hopkinton, MA: December 1996 September 1997. I was part of the manufacturing team that produced a bone-matter/protein paste to be used for patients with severely broken bones for phase 2 studies. Duties included making large and small-scale chemical batches for the company, following and filling SOP documents, maintaining GMP process areas.Americorps, Merritt Island National Wildlife Refuge, Titusville, FL: May 1994- November 1996. Worked with the staff of MINWR on projects including Sea Turtle Management, Marsh-Bird management, weather documentation, and several Threatened Species projects. Duties included collecting, maintaining and presenting data on populations of species, trapping and tracking animals, creating a project to re-introduce a displaced species into a new habitat, recovering and treating animals hurt from Space Shuttle launches & other aspects of the space program, and public relations.Animal Husbandry Technician, UMASS Medical Center Diabetes Research Division, Worcester, MA: September 1993-May 1994. Cared for a collection of 1,800 Immune-suppressed and diabetic rats for the group of researchers. Responsible for testing and treating some of the rats, doing blood glucose testing, insulin injections, urine testing, husbandry, setting up breeding colonies record keeping and reporting. Responsible for cell culture and setting up FACS experiments.Skills/Training/Certifications:Introduction to Image-Pro Plus, 2007Customizing Image-Pro Plus with Scripting, 2007PCR, Cell Culture, Protein Expression, Advanced PCR. Life Technologies, 1999-2001.Continuing Education: Boston University, Molecular and Microbiology, 1996-1997.Johns Hopkins University, (Microscopy), 2001-2002.Other skills include:Molecular biology techniques, cell culture techniques, animal handling, record keeping, protocol development, maintaining and repairing lab equipment, statistical analysis, document presentation, ELISA, light, fluorescence and electron Microscopy and sample prep, Real-Time PCR, and FACS.Publications:Thomas A, Redon CE, Sciuto L, Padiernos E, Ji J, Lee MJ, Yuno A, Lee S, Zhang Y, Tran L, Yutzy W, Rajan A, Guha U, Chen H, Hassan R, Alewine CC, Szabo E, Bates SE, Kinders RJ, Steinberg SM, Doroshow JH, Aladjem MI, Trepel JB, Pommier Y. Phase I Study of ATR Inhibitor M6620 in Combination with Topotecan in Patients With Advanced Solid Tumors. J Clin Oncol. 2017 Dec 18: JCOPHONE NUMBER AVAILABLE doi: 10.1200/JCO.PHONE NUMBER AVAILABLEFerry-Galow KV, Makhlouf HR, Wilsker DF, Lawrence SM, Pfister TD, Marrero AM, Bigelow KM, YutzyWH, Ji JJ, Butcher DO, Gouker BA, Kummar S, Chen AP, Kinders RJ, Parchment RE, Doroshow JH. The root causes of pharmacodynamic assay failure. Semin Oncol. 2016 Aug;43(4):484-91. doi: 10.1053/j.seminoncol.2016.06.006. Epub 2016 Jun 15.Kummar S, Chen A, Gutierrez M, Pfister TD, Wang L, Redon C, Bonner WM, Yutzy W, Zhang Y, Kinders RJ, Ji J, Allen D, Covey JM, Eiseman JL, Holleran JL, Beumer JH, Rubinstein L, Collins J, Tomaszewski J, Parchment R, Pommier Y, Doroshow JH. Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2016 Jul;78(1):73-81. doi: 10.1007/sPHONE NUMBER AVAILABLE Epub 2016 May 11.Roden RB, Yutzy WH 4th, Fallon R, Inglis S, Lowy DR, Schiller JT. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology. 2000 May 10;270(2):254-7.Roden RB, Day PM, Bronzo BK, Yutzy WH 4th, Yang Y, Lowy DR, Schiller JT. Positively charged termini of the L2 minor capsid protein are necessary for papillomavirus infection. Journal of Virology. 2001 Nov;75(21):10493-7.Yang R, Day PM, Yutzy WH 4th, Lin KY, Hung CF, Roden RB. Cell surface-binding motifs of L2 that facilitate papillomavirus infection. Journal of Virology. 2003 Mar;77(6):3531-41.Yang R, Yutzy WH 4th, Viscidi R, and RBS Roden. Interaction of L2 with b-actin facilitates intracellular transport of papillomavirus and infection. Journal of Biological Chemistry. 2003 Apr 4;278(14):12546-53.Yang R, Yutzy WH 4th, Viscidi RP, Roden RB. Interaction of L2 with beta-actin directs intracellular transport of papillomavirus and infection. Journal of Biological Chemistry. 2003 Apr 4;278(14):12546-53. Epub 2003 Jan 30.Yang R, Francisco MM, Lin KY, Yutzy WH 4th, Uematsu S, Takeda K, Akira S, Viscidi RP, and Roden RBS. Human papillomavirus type-16 virus-like particles activate complimentary defense responses in key dendritic cell subpopulations. Journal of Immunology. 2004 Aug 15;173(4):2624-31.Alyson Fay, Candidate's Name IV, Richard BS Roden, Junona Moroianu. The Positively Charded Termini of BPV1 L2 Minor Capsid Protein Required for Bovine Papillomavirus Infection Function Separately in Nuclear Import and DNA Binding. J Virol. 2004 Dec;78(24):13447-54.Trimble CL, Piantadosi S, Gravitt P, Ronnett B, Pizer E, Elko A, Wilgus B, Yutzy W, Daniel R, Shah K, Peng S, Hung C, Roden R, Wu TC, Pardoll D. Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype. Clin Cancer Res. 2005 Jul 1;11(13):4717-23.Yang R, Francisco MM, Cui H, Lin KY, Yutzy WH 4th, Uematsu S, Takeda K, Akira S, Viscidi RP, and Roden RBS. Induction of Activation-Induced Cytidine Deaminase and Ig Class Switch Recombination by Papillomavirus-like Particles Requires MyD88. Submitted.Patti E. Gravitt, Sathish Naranyanan, Steven Piantadosi, Brigitte Ronnett, Ellen Pizer, Andrea Elko, Barbara Wilgus, Candidate's Name , Richard Daniel, Keerti Shah, Shiwen Peng, Chienfu Hung, Richard Roden, Tzyy Choou Wu, Drew Pardoll, Cornelia L. Trimble. High grade CIN 2/3 regression is associatedwith decreasing HPV 16 viral load and inos expression levels. Accepted, Cancer Epidemiology, Biomarkers & Prevention. Submitted.Yang R, Cai Z, Zhang Y, Yutzy WH 4th, Roby KF, Roden RB. CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res. 2006 Jul 1;66(13):6807-15.Yang R, Murillo FM, Delannoy MJ, Blosser RL, Yutzy WH 4th, Uematsu S, Takeda K, Akira S, Viscidi RP, Roden RB. B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88.J Immunol. 2005 Jun 15;174(12):7912-9.Fay A, Yutzy WH 4th, Roden RB, Moroianu J. The positively charged termini of L2 minor capsid protein required for bovine papillomavirus infection function separately in nuclear import and DNA binding. J Virol. 2004 Dec;78(24):13447-54. |
